Processa Pharmaceuticals (PCSA) announced the pricing of a public offering of 28M shares of common stock at a public offering price of 25c per share. The closing of the offering is expected to occur on or about June 18. H.C. Wainwright is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $7M. Processa intends to use the net proceeds from the offering to continue the Phase 2 clinical trial for NCG-Cap.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Processa sees 28M shares at 25c in public offering
- Processa Pharmaceuticals Announces Licensing Deal with Intact
- Processa Pharmaceuticals signs binding term sheet with Intact Therapeutics
- Processa Pharmaceuticals files to sell 20.59M shares of common stock, warrants
- Processa to engage potential partners, investors at BIO International Convention